From APOE Genetics to AI-Designed Drug Candidates: An Integrated Pipeline for Oral, Brain-Penetrant ACAT1 Inhibitors in Alzheimer's Disease
Sharad Agarwal, Rory Popert, Paul‐Michael Agapow, Crystal A. Ruff, Shikta Gupta
This paper presents an AI-driven drug discovery platform for designing oral, brain-penetrant ACAT1 inhibitors for Alzheimer's disease, identifying promising lead candidates with favorable properties.
bioRxiv · May 26, 2026 · PreprintNeuroscience